Primary intestinal diffuse large B-cell lymphoma: novel insights and clinical perception

Area of Science:

• Oncology
• Hematology
• Gastroenterology

Background:

• Extranodal Non-Hodgkin lymphoma (NHL) frequently involves the gastrointestinal (GI) tract.
• Primary intestinal diffuse large B-cell lymphoma (PI-DLBCL) is a rare extranodal lymphoma with distinct clinical characteristics.

Purpose of the Study:

• To investigate the clinical features and prognostic factors of PI-DLBCL.
• To enhance understanding for improved diagnosis and treatment strategies.

Main Methods:

• Retrospective analysis of clinical data from 88 PI-DLBCL patients.
• Univariate and multivariate Cox regression for prognostic factor analysis.
• Kaplan-Meier survival analysis and literature review.

Main Results:

• PI-DLBCL predominantly affects males (68.18%) with a median age of 57; abdominal pain is the most common symptom (70.45%).
• Surgery combined with R-CHOP chemotherapy was the primary first-line treatment.
• Lugano stage, ECOG score, B symptoms, IPI score, and laboratory markers (WBC, LDH, albumin, β2M) significantly influenced OS and PFS.

Conclusions:

• PI-DLBCL is more common in middle-aged to elderly men, often presenting with non-specific symptoms.
• Surgery plus chemotherapy is the standard initial treatment.
• The Lugano stage emerges as an independent prognostic factor for both OS and PFS in PI-DLBCL.